This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2005 Feb 9;293(6):736-9.

doi: 10.1001/jama.293.6.736.

Ximelagatran--promises and concerns

Victor Gurewich

PMID: 15701916
DOI: 10.1001/jama.293.6.736

Editorial

Ximelagatran--promises and concerns

Victor Gurewich. JAMA. 2005.

. 2005 Feb 9;293(6):736-9.

doi: 10.1001/jama.293.6.736.

Author

Victor Gurewich

PMID: 15701916
DOI: 10.1001/jama.293.6.736

No abstract available

PubMed Disclaimer

Comment in

Safety of ximelagatran.
Brinker A, He R, Desai M, Gelperin K, Robie-Suh K. Brinker A, et al. JAMA. 2005 Jun 15;293(23):2859; author reply 2859-60. doi: 10.1001/jama.293.23.2859-a. JAMA. 2005. PMID: 15956625 No abstract available.

Comment on

Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS; THRIVE Treatment Study Investigators. Fiessinger JN, et al. JAMA. 2005 Feb 9;293(6):681-9. doi: 10.1001/jama.293.6.681. JAMA. 2005. PMID: 15701909 Clinical Trial.
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A; SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Albers GW, et al. JAMA. 2005 Feb 9;293(6):690-8. doi: 10.1001/jama.293.6.690. JAMA. 2005. PMID: 15701910 Clinical Trial.
Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL, Gage BF. O'Brien CL, et al. JAMA. 2005 Feb 9;293(6):699-706. doi: 10.1001/jama.293.6.699. JAMA. 2005. PMID: 15701911

Similar articles

Cost-effectiveness of ximelagatran for stroke prevention.
Perret-Guillaume C, Wahl D. Perret-Guillaume C, et al. JAMA. 2005 Jun 15;293(23):2860-1; author reply 2861. doi: 10.1001/jama.293.23.2860. JAMA. 2005. PMID: 15956626 No abstract available.
Ximelagatran or warfarin in atrial fibrillation?
Epstein EF. Epstein EF. Lancet. 2004 Feb 28;363(9410):736; author reply 736. doi: 10.1016/S0140-6736(04)15679-1. Lancet. 2004. PMID: 15001338 No abstract available.
Ximelagatran or warfarin in atrial fibrillation?
Eikelboom J, Hankey G. Eikelboom J, et al. Lancet. 2004 Feb 28;363(9410):734; author reply 734, 736. doi: 10.1016/S0140-6736(04)15675-4. Lancet. 2004. PMID: 15001334 No abstract available.
The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials.
Salam AM, Al-Mousa EN. Salam AM, et al. Expert Opin Pharmacother. 2004 Jun;5(6):1423-30. doi: 10.1517/14656566.5.6.1423. Expert Opin Pharmacother. 2004. PMID: 15163285 Review.
Ximelagatran in the clinic: practical management of patients.
Schulman S, Lip GY. Schulman S, et al. Semin Vasc Med. 2005 Aug;5(3):301-7. doi: 10.1055/s-2005-916170. Semin Vasc Med. 2005. PMID: 16123918 Review.

See all similar articles

Cited by

Implication from randomized trials of rate and rhythm controls on management of patients with persistent atrial fibrillation.
Hagens VE, Van Veldhuisen DJ, Crijns HJ, van Gelder IC. Hagens VE, et al. Ann Noninvasive Electrocardiol. 2006 Apr;11(2):170-86. doi: 10.1111/j.1542-474X.2006.00099.x. Ann Noninvasive Electrocardiol. 2006. PMID: 16630092 Free PMC article. Review.
Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics.
Thompson LE, Davis BH, Narayan R, Goff B, Brown TM, Limdi NA. Thompson LE, et al. Clin Pharmacol Ther. 2023 Mar;113(3):585-599. doi: 10.1002/cpt.2714. Epub 2022 Aug 4. Clin Pharmacol Ther. 2023. PMID: 35857814 Free PMC article. Review.
Antithrombotic medication for cardioembolic stroke prevention.
Font MÀ, Krupinski J, Arboix A. Font MÀ, et al. Stroke Res Treat. 2011;2011:607852. doi: 10.4061/2011/607852. Epub 2011 Jun 22. Stroke Res Treat. 2011. PMID: 21822469 Free PMC article.
Pulmonary embolism: current treatment options.
Meysman M, Haentjens P. Meysman M, et al. Curr Treat Options Cardiovasc Med. 2005 Dec;7(6):483-90. doi: 10.1007/s11936-005-0034-y. Curr Treat Options Cardiovasc Med. 2005. PMID: 16283976
Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke.
McCabe DJ, Rakhit RD. McCabe DJ, et al. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):14-24. doi: 10.1136/jnnp.2006.092031. J Neurol Neurosurg Psychiatry. 2007. PMID: 17172564 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information